NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 21.34 against a street estimate of 20.34 — a beat of 4.9%.
with an average price target of ₹3,585.79.
CONFIDENT Strong Q1 FY27 start: 25% revenue growth, 31% PAT growth. India outperforming market; Africa branded surging 30%; Asia disrupted by geopolitical issues, expected recovery Q2+. Maintaining high-teens full-year guidance. Q1 FY27 India strong across therapies; Asia hit by Middle East geopolitical disruption (sales push to Q2); Africa robust branded growth and field expansion paying off; U.S. elevated but expected to normalize. Analysts pressed Asia recovery confidence (visibility soft), U.S. guidance credibility post-blockbuster Q1 (competitive pressures acknowledged), and India execution vs IPM data (IQVIA tracking issues blamed). Management deferred hard quantification, emphasizing qualitative visibility and maintaining disciplined guidance. 2026-07-30…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ajanta Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.